Xbrane Biopharma’s Shares Offering

Baker McKenzie advised Xbrane Biopharma on the deal. Xbrane Biopharma AB (publ) executed a primary issuance of shares of approximately SEK 170 million at a subscription price...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here